Skip to main content

Table 2 Demographic and clinical characteristics of 640 patients enrolled in both the intervention and control groups

From: Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam

Variables Total (n = 640) Control (n = 308) Intervention (n = 332) P-value**
n (%) n (%) n (%)
Age Median (IQR) 31.9 (28.2–35.1) 31.7 (28.2–34.5) 32.1 (28.4–35.6)  
<35 years old 474 (74.1) 235 (76.3) 239 (72.0) 0.21
≥35 years old 166 (25.9) 73 (23.7) 93 (28.0)
Sex Male 452 (70.6) 216 (70.1) 236 (71.1) 0.79
Female 188 (29.4) 92 (29.9) 96 (28.9)
Marital status Single 195 (30.5) 89 (28.9) 106 (32.0) 0.44
Married/divorced 445 (69.5) 219 (71.7) 226 (68.1)
ART-naïve status Naïve 606 (94.7) 289 (45.2) 317 (49.5) 0.35
Non-naïve 35 (6.0) 19 (6.2) 16 (4.8)
History of OIs* Yes 182 (28.4) 91 (29.5) 91 (27.4) 0.55
No 458 (71.6) 217 (70.5) 241 (72.6)
Occupation Employed 493 (77.0) 243 (78.9) 250 (75.3) 0.31
Unemployed 147 (23.0) 65 (21.1) 82 (24.7)
Time to be known infected ≥6 months <6 months HIV- 156 (24.4) 69 (22.4) 87 (26.2) 0.31
  449 (70.0) 220 (71.0) 229 (69.0)
HIV transmission route (self-reported) IV Drug use 297 (46.4) 136 (44.2) 161 (48.5) 0.27
Sexual and others 343 (53.6) 172 (55.8) 171 (51.5)
History of IDU Yes 337 (52.7) 151 (49.0) 186 (56.0) 0.08
No 303 (47.3) 157 (51.0) 146 (44.0)
Viral hepatitis Yes 207 (33.7) 92 (31.1) 115 (36.2) 0.18
No 407 (36.3) 204 (68.9) 203 (63.8)
History of TB Yes treatment 99 (15.5) 53 (17.2) 46 (13.9) 0.24
No 541 (84.5) 255 (82.8) 286 (86.1)
Having an HIV infected family member Yes 256 (40.0) 132 (42.9) 124 (37.3) 0.09
No 384 (60) 176 (57.1) 208 (62.7)
WHO clinical stage Clinical stage 1 or 2 298 (46.6) 142 (46.1) 156 (47.0) 0.82
Clinical stage 3 or 4 342 (53.4) 166 (53.9) 176 (53.0)
BMI” 18+ kg/m2 409 (64.0) 188 (61.0) 221 (66.7) 0.15
<18 kg/m2 231 (36.0) 120 (39.0) 111 (33.3)
Hemoglobin level <100 g/L 73 (11.4) 33 (10.7) 40 (12.0) 0.61
≥100 g/L 520 (81.2) 253 (82.1) 267 (80.4)
CD4 counts Median (IQR) 83 (29–176) 82 (27–183) 84 (30–168) 0.90
<100 cells/μl 359 (56.1) 172 (55.8) 187 (56.3)
>100 cells/μl 281 (43.9) 136 (44.2) 145 (43.7)
VL at baseline (copies/ml) <100.000 426 (66.7) 209 (67.9) 217 (65.6) 0.54
≥100,000 213 (33.3) 99 (32.1) 114 (34.4)
regimen D4T/3TC/NVP ART^ 533 (83.3) 258 (83.8) 275 (82.8) 0.75
Other regimens 107 (16.7) 50 (16.2) 57 (17.2)
Clinics Halong CDC 307 (48.0) 168 (54.5) 139 (41.9) 0.001
Other clinics 333 (52.0) 140 (45.5) 193 (58.1)
  1. *OIs opportunistic infections, IDU Injecting drug use, TB tuberculosis, BMI Body Mass Index, ART Antiretroviral therapy, VL viral load
  2. **Chi-square test